肥満の薬剤療法のためのアミリンペプチド受容体活性化剤のレビュー

Sangmin Lee¹

¹Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan, 49315, Republic of Korea.

Current drug targets

|September 5, 2025

まとめ

アミリン受容体活性化剤は,肥満の治療において有望であり,併用療法では,既存の治療法と比較して,より高い有効性と,より高い安全性がある可能性がある.

科学分野:

内分泌学
薬理学について
代謝疾患

背景:

アミリンはペプチドホルモンで,インスリンと共に分泌され,血糖と食欲を調節する.
アミリン受容体は,カルシトニン受容体と受容体活性調節タンパク質のヘテロディマーであり,代謝障害の主要な標的である.
アミリン受容体の活性化が糖尿病と肥満の治療に有望な戦略です

研究の目的:

肥満に対する臨床試験における現在のアミリン受容体活性化剤の検討
アミリンアナログの開発と薬物投与における最近の進歩を強調する.
アミリンベースの肥満治療の潜在的な利点と課題について議論する.

主な方法:

最近の研究出版物と薬の開発情報に関する文献検索
アミリン受容体活性化剤の臨床試験データの分析
拡張作用のための脂化を含むペプチド薬の開発戦略のレビュー.

主要な成果:

肥満の治療のためにいくつかのアミリン類が臨床試験中です.
変異はアミリン受容体の親和性と効力を強化した.
アミリンアナログと他の抗肥満薬との併用療法により有効性が向上しています.
アミリン受容体活性化剤は,GLP-1受容体活性化剤よりも好ましい副作用のプロファイルを持つ可能性があります.

結論:

アミリン受容体活性化剤は肥満の薬剤療法における重要な進歩です
併用療法がアミリンベースの肥満治療の第一線となる可能性が高い.
アミリン類のさらなる研究により,代謝疾患の管理が改善される可能性がある.

キーワード:

アミリンアフィニティカルシトニン肥満ペプチドホルモン効き目がある

さらに関連する動画

11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.4K

05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

346

関連する概念動画

01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...

01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

関連する実験動画